RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa

  • Regulatory authorities in South Africa have signed off RedHill Biopharma Ltd's RDHL Phase 2/3 study evaluating RHB-107 (upamostat) for non-hospitalized patients with symptomatic COVID-19. 
  • The study is already ongoing in the U.S., with an expansion of study sites underway to further accelerate recruitment.
  • RHB-107 is an oral antiviral drug candidate that targets human serine proteases that prepare the spike protein for viral entry into target cells. 
  • The 2-part study is designed for dose selection and to evaluate time to a sustained recovery from illness as the primary endpoint. Patients are also tested for specific viral strain.
  • In parallel, top-line results are upcoming from the opaganib global 475-patient Phase 2/3 study in patients hospitalized with severe COVID-19.
  • Related Content: RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant.
  • Price Action: RDHL shares are up 0.25% at $8.10 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!